Bisphosphonate therapy in CKD: the current state of affairs.

摘要: Purpose of review Chronic kidney disease (CKD) is associated with the development mineral and bone disorders (MBD), including renal osteodystrophy (ROD). ROD a global disorder strength that an increased fracture risk. The use bisphosphonates for risk reduction in CKD remains controversial. This provides synopsis state-of-the literature regarding safety potential antifracture benefits patients. Recent findings In preclinical studies animals 3-4 evidence CKD-MBD, resulted changes quality improve strength. Bone turnover was generally reduced to similar extent without CKD. Post hoc analyses randomized trials patients reported increases density (BMD) were There are no primary clinical trial data CKD-MBD. Summary should follow general population guidelines. lack 4-5D CKD-MBD makes treatment decisions challenging. Clinical urgently needed provide on these cohorts.